Rosetta Genomics Ltd (ROSGQ)

[mlkrborn]

study published:
Rosetta Genomics: Study validating miRview mets2 published in The Oncologist says 'vast majority of samples resulting in a single reported origin, which was accurate in 90% of the cases' (ROSG) 15.48 -0.81 : The article provides an in-depth description of the test, its development and its mechanism of action. In the study, the assay was first validated on 509 samples of known origin in a blinded manner and demonstrated 85% accuracy, with the vast majority of samples resulting in a single reported origin, which was accurate in 90% of the cases. The study then extended the validation to CUP, which is the most difficult diagnostic challenge for a test designed to identify tumor origin. The investigators performed validation of the assay on CUP cases, assessing the performance of the assay using clinico-pathologic evaluation, and demonstrated that the performance of the assay remains the same for these challenging cases. This high level of accuracy in identifying the tumor-of-origin were similar to the 92% concordance demonstrated in a study conducted in Greece and recently presented at the United States and Canadian Academy of Pathology.